London · Delayed Price · Currency is GBP · Price in GBX Oxford Biomedica Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 33% year-over-year to GBP 170.9 million, with first full year of EBITDA profitability and strong cash position. U.S. expansion, a robust order backlog, and multi-vector capabilities support above-market growth targets for 2026 and beyond.
-
A focused CDMO in Cell and Gene Therapy reported strong order growth, expanded U.S. operations with a new Durham facility, and enhanced financial flexibility. Innovation and operational improvements support ambitious revenue and profitability targets for 2025–2028.
-
A global CDMO specializing in viral vectors for cell and gene therapy is expanding its US and EU footprint, achieving strong revenue growth and targeting 25–30% annual growth through 2028. Recent investments and acquisitions support capacity, while innovation and expertise drive competitive advantage.
-
H1 2025 saw 44% revenue growth and a 166% rise in contracted orders, with profitability improving and a strengthened balance sheet. Strategic investments and a robust pipeline support guidance for sustained double-digit growth and margin expansion through 2028.
Fiscal Year 2024
-
Organic revenue grew 81% and total revenue rose 44% to GBP 128.8 million in 2024, with strong commercial momentum and a narrowed EBITDA loss. 2025 guidance targets GBP 160–170 million in revenue and a return to profitability, supported by a robust pipeline and high order coverage.
-
Strong H1 2024 organic revenue growth of 38% and a maturing pipeline drove improved financials, with reduced losses and a robust order book. Guidance for 2024–2026 remains unchanged, supported by high suite utilization and strong commercial momentum.